Previous 10 | Next 10 |
Agenus (NASDAQ: AGEN ): Q3 GAAP EPS of -$0.33 beats by $0.05 . Revenue of $19.94M (+55.8% Y/Y) beats by $4.34M . Press Release More news on: Agenus Inc., Earnings news and commentary, Healthcare stocks news,
LEXINGTON, Mass. , Nov. 4, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 , and cancer vaccines provided a corporate update and reported financial results for the third quarter of...
LEXINGTON, Mass. , Oct. 31, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial results before the market opens on Monday, November 4, 2019...
$750 million charge in Allergan’s 3Q 2019 earnings Allergan plc’s ( AGN ) 3Q-2019 earnings will have a $750 million pre-tax GAAP charge. According to the company’s announcement on 10/28/2019, its subsidiaries, Forest Laboratories, LLC, Forest Laboratories, Inc. and F...
Immuno-oncology company Agenus (NASDAQ: AGEN ) is 2.1% lower after hours following a filing by shareholder Gilead Sciences (NASDAQ: GILD ) to offer up to 11.1M shares. More news on: Agenus Inc., Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move Read more ...
Cancer drug sales are on track to post an impressive compound annual growth rate of 11.4% over the next five years, according to a report by EvaluatePharma. This double-digit growth rate is particularly noteworthy because cancer drug sales already dwarf all other pharma market segments by a wide...
LEXINGTON, Mass., Sept. 30, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, announced today that Jennif...
Today, we want to share our analysis of Agenus ( AGEN ) with you. Over the last year, its stock fluctuated largely, falling from ~$3.67 in January 2019 to ~$2.6 in August 2019. Recently, the company’s stock price grew by over 15%, driven by the IND acceptance for AGEN2373. The company...
Agenus, Inc. (AGEN) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Jennifer Buell – Chief Operating Officer Garo Armen – Chairman and Chief Executive Officer Paisley Myers – Senior Scientist Christine Klaskin – Vice P...
Agenus ( AGEN +8% ) is up on light volume in early trade on the heels of its announcement that the FDA has accepted its IND filing for immuno-oncology (I-O) candidate AGEN2373, triggering a $7.5M milestone payment from collaboration partner Gilead Sciences ( GILD ). More news on: ...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...